CY1110186T1 - Συνθεση ινσουλινοτροπου πεπτιδιου - Google Patents

Συνθεση ινσουλινοτροπου πεπτιδιου

Info

Publication number
CY1110186T1
CY1110186T1 CY20101100519T CY101100519T CY1110186T1 CY 1110186 T1 CY1110186 T1 CY 1110186T1 CY 20101100519 T CY20101100519 T CY 20101100519T CY 101100519 T CY101100519 T CY 101100519T CY 1110186 T1 CY1110186 T1 CY 1110186T1
Authority
CY
Cyprus
Prior art keywords
fragments
phase
solid phase
solution
fragment
Prior art date
Application number
CY20101100519T
Other languages
English (en)
Inventor
Lin Chen
Yeun-Kwei Han
Christopher R Roberts
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1110186T1 publication Critical patent/CY1110186T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αφορά στην παρασκευή ινσουλινοτρόπων πεπτιδίων που συντίθενται με χρήση μιας προσέγγισης στερεάς φάσης και μιας φάσης διαλύματος («υβριδικής»). Γενικά, η προσέγγιση περιλαμβάνει τη σύνθεση τριών διαφορετικών ενδιάμεσων πεπτιδικών θραυσμάτων με χρήση χημείας στερεάς φάσης. Στη συνέχεια χρησιμοποιείται η χημεία φάσης διαλύματος προκειμένου να προστεθεί επιπλέον αμινοξικό υλικό σε ένα από τα θραύσματα. Στη συνέχεια τα θραύσματα συζευγνύονται μεταξύ τους σε στερεά φάση και σε φάση διαλύματος. Η χρήση μιας ψευδοπρολίνης σε ένα από τα θραύσματα διευκολύνει τη σύνθεση στερεάς φάσης του θραύσματος αυτού και επίσης διευκολύνει τη μετέπειτα σύζευξη σε φάση διαλύματος αυτού του θραύσματος με άλλα θραύσματα. Η παρούσα εφεύρεση είναι πολύ χρήσιμη για τη δημιουργία ινσουλινοτρόπων πεπτιδίων του τύπου του GLP-1(7-36) και των φυσικών και των μη φυσικών αναλόγων αυτού.
CY20101100519T 2006-06-23 2010-06-11 Συνθεση ινσουλινοτροπου πεπτιδιου CY1110186T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81591906P 2006-06-23 2006-06-23
EP07765481A EP2035451B1 (en) 2006-06-23 2007-06-19 Insulinotropic peptide synthesis

Publications (1)

Publication Number Publication Date
CY1110186T1 true CY1110186T1 (el) 2015-01-14

Family

ID=38596729

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100519T CY1110186T1 (el) 2006-06-23 2010-06-11 Συνθεση ινσουλινοτροπου πεπτιδιου

Country Status (33)

Country Link
US (2) US20080004429A1 (el)
EP (1) EP2035451B1 (el)
JP (1) JP4537495B2 (el)
KR (1) KR101087859B1 (el)
CN (1) CN101563364B (el)
AR (1) AR061604A1 (el)
AT (1) ATE466881T1 (el)
AU (1) AU2007263043B2 (el)
BR (1) BRPI0713575A2 (el)
CA (1) CA2654610C (el)
CL (1) CL2007001835A1 (el)
CR (1) CR10463A (el)
CY (1) CY1110186T1 (el)
DE (1) DE602007006310D1 (el)
DK (1) DK2035451T3 (el)
EC (1) ECSP088999A (el)
ES (1) ES2341588T3 (el)
HR (1) HRP20100302T1 (el)
IL (1) IL195421A0 (el)
MA (1) MA30530B1 (el)
MX (1) MX2008015935A (el)
MY (1) MY144608A (el)
NO (1) NO20084863L (el)
NZ (1) NZ573093A (el)
PL (1) PL2035451T3 (el)
PT (1) PT2035451E (el)
RS (1) RS51281B (el)
RU (1) RU2448978C2 (el)
SI (1) SI2035451T1 (el)
TW (1) TWI331155B (el)
UA (1) UA96602C2 (el)
WO (1) WO2007147816A1 (el)
ZA (1) ZA200810072B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5473925B2 (ja) 2007-10-27 2014-04-16 コーデン ファーマ コロラド インコーポレイテッド 固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成
EP2222695A2 (en) * 2007-12-11 2010-09-01 F. Hoffmann-La Roche AG Insulinotropic peptide synthesis using solid and solution phase combination techniques
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US20100183876A1 (en) * 2008-12-23 2010-07-22 Hell Andre Process for the Preparation of a Peptide Powder Form
CN102414220A (zh) * 2009-05-01 2012-04-11 霍夫曼-拉罗奇有限公司 使用固相和液相组合技术的促胰岛素肽合成
US20110313131A1 (en) 2010-06-21 2011-12-22 Christelle Carl Reversed phase hplc purification of a glp-1 analogue
US20120157382A1 (en) 2010-12-21 2012-06-21 Siegfried Krimmer Pharmaceutical glp-1 compositions having an improved release profile
DK2788110T3 (en) * 2011-12-08 2019-02-11 Pentair Water Pool & Spa Inc AQUACULTURE SYSTEM AND PROCEDURE TO OPERATE A PUMP IN SUCH A SYSTEM
RU2643515C2 (ru) 2011-12-29 2018-02-02 Ново Нордиск А/С Дипептид, содержащий непротеиногенную аминокислоту
CN104936610A (zh) 2012-11-13 2015-09-23 益普生制药股份有限公司 Glp-1类似物的纯化方法
WO2014077801A1 (en) 2012-11-13 2014-05-22 Ipsen Pharma S.A.S. Purification process for preparing highly pure taspoglutide
GR20140100479A (el) * 2014-09-23 2016-05-05 Novetide, Ltd., Συνθεση λιραγλουτιδης
CA3093221A1 (en) 2018-03-09 2019-09-12 Enzypep B.V. Chemo-enzymatic synthesis of liraglutide, semaglutide and glp-1
EP3762408A1 (en) 2018-03-09 2021-01-13 Enzypep B.V. Chemo-enzymatic synthesis of semaglutide, liraglutide and glp-1
ES2938734T3 (es) * 2018-10-09 2023-04-14 Fresenius Kabi Ipsum S R L Procedimiento para la fabricación de análogos de GLP-1
TWI738260B (zh) 2019-03-25 2021-09-01 台灣神隆股份有限公司 純化利拉魯肽之方法
CN114401981A (zh) * 2019-06-18 2022-04-26 北京费森尤斯卡比医药有限公司 胰高血糖素制造方法
EP3753946A1 (en) 2019-06-18 2020-12-23 Fresenius Kabi iPSUM S.r.l. Improved process for the preparation of high purity glucagon
US20230406900A1 (en) * 2022-06-01 2023-12-21 Scinopharm Taiwan, Ltd. Process for preparing glucagon-like peptide-1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281335B1 (en) * 1993-10-08 2001-08-28 Coulter Corporation Hybridoma and anti-KC-4 humanized monoclonal antibody
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0820296A4 (en) * 1995-04-14 1999-06-30 Univ Tulane ANALOGS OF THE GROWTH HORMONE-RELEASING FACTOR
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6903186B1 (en) * 1998-12-07 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S Analogues of GLP-1
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2005063792A2 (en) * 2003-12-31 2005-07-14 F. Hoffmann-La Roche Ag Methods for recovering cleaved peptide from a support

Also Published As

Publication number Publication date
CN101563364A (zh) 2009-10-21
WO2007147816A1 (en) 2007-12-27
JP4537495B2 (ja) 2010-09-01
TW200811195A (en) 2008-03-01
KR101087859B1 (ko) 2011-11-30
CL2007001835A1 (es) 2008-03-14
EP2035451B1 (en) 2010-05-05
US20110213082A1 (en) 2011-09-01
RS51281B (sr) 2010-12-31
MA30530B1 (fr) 2009-06-01
PT2035451E (pt) 2010-06-09
AU2007263043A1 (en) 2007-12-27
JP2009541257A (ja) 2009-11-26
RU2448978C2 (ru) 2012-04-27
ATE466881T1 (de) 2010-05-15
EP2035451A1 (en) 2009-03-18
UA96602C2 (ru) 2011-11-25
ES2341588T3 (es) 2010-06-22
DK2035451T3 (da) 2010-06-07
TWI331155B (en) 2010-10-01
IL195421A0 (en) 2011-08-01
BRPI0713575A2 (pt) 2013-02-13
ZA200810072B (en) 2009-12-30
AU2007263043B2 (en) 2012-11-29
NZ573093A (en) 2012-01-12
CA2654610A1 (en) 2007-12-27
DE602007006310D1 (el) 2010-06-17
CA2654610C (en) 2012-03-20
AR061604A1 (es) 2008-09-10
NO20084863L (no) 2009-01-22
SI2035451T1 (sl) 2010-06-30
US20080004429A1 (en) 2008-01-03
ECSP088999A (es) 2009-01-30
MY144608A (en) 2011-10-14
RU2009101969A (ru) 2010-07-27
CR10463A (es) 2009-02-26
PL2035451T3 (pl) 2010-08-31
CN101563364B (zh) 2014-04-02
HRP20100302T1 (hr) 2010-06-30
MX2008015935A (es) 2009-01-13
KR20090023619A (ko) 2009-03-05

Similar Documents

Publication Publication Date Title
CY1110186T1 (el) Συνθεση ινσουλινοτροπου πεπτιδιου
MX2010006044A (es) Sintesis de peptidos insulinotropicos utilizando una combinacion de tecnicas en fase solida y en solucion.
CY1113850T1 (el) Νεα παραγωγα ινσουλινης
RU2559320C2 (ru) Новые аналоги глюкагона
CY1117710T1 (el) Κρυσταλλικοι αναστολεις πρωτεασων εποξυ-κετονων πεπτιδιων και η συνθεση των κετο-εποξειδιων αμινοξεων
BRPI0507623A (pt) peptìdeos da famìlia da amilina e métodos para prepará-los e empregá-los
Dekan et al. Total synthesis of human hepcidin through regioselective disulfide‐bond formation by using the safety‐catch cysteine protecting group 4, 4′‐dimethylsulfinylbenzhydryl
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
Liu et al. A synthetic route to human insulin using isoacyl peptides
PE20090726A1 (es) Anticuerpos anti-ige apoptoticos
AR080229A1 (es) Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23)
BRPI0509595A (pt) processo para a preparação de bissulfato de atazanavir, composto, formulação farmacêutica compreendendo os mesmos e uso
CY1116917T1 (el) Αναλογα οξυντομοντουλινης
GEP20146112B (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof
PE20120543A1 (es) Anticuerpo anti-tau ps422
BR112012009854B8 (pt) proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma
ECSP077282A (es) Proceso para la concentración de anticuerpos y productos terapéuticos de los mismos
JP2014224121A5 (el)
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
BRPI0513426A (pt) processo de preparação de amino ácidos úteis na preparação de moduladores de receptores de peptìdeos
WO2009155258A3 (en) Glucagon/glp-1 receptor co-agonists
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
SI3079715T1 (en) A mixture of peptides
Sohma et al. Contribution of Residue B5 to the Folding and Function of Insulin and IGF-I: CONSTRAINTS AND FINE-TUNING IN THE EVOLUTION OF A PROTEIN FAMILY 2
DK1773994T3 (da) Polypeptid